XML 24 R7.htm IDEA: XBRL DOCUMENT v3.25.0.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Cash flows from operating activities      
Net loss $ (50,420) $ (61,685) $ (74,412)
Adjustments to reconcile net loss to net cash used in operating activities:      
Depreciation and amortization 5,297 5,133 3,722
Stock-based compensation 22,254 16,458 10,833
Provision for bad debts 2,449 1,440 1,598
Amortization of operating lease right-of-use assets 723 734 775
Amortization of debt discount and issuance costs 1,147 1,116 1,086
Deferred income taxes (21) 5 (18)
Revaluation of contingent royalty obligation to Evolus Founders 7,176 4,257 5,755
Non-cash in-process research and development expense 0 4,429 0
Changes in assets and liabilities:      
Inventories 3,252 4,193 (10,688)
Accounts receivable (19,602) (9,521) (9,389)
Prepaid expenses 2,351 (1,798) 1,180
Other assets 706 (864) 4,854
Accounts payable 391 (1,017) 968
Accrued expenses 7,014 9,019 (5,199)
Accrued litigation settlement 0 (5,000) (15,000)
Operating lease liabilities (716) (907) (977)
Net cash used in operating activities (17,999) (34,008) (84,912)
Cash flows from investing activities      
Purchases of property and equipment (1,472) (473) (1,618)
Additions to capitalized software (3,351) (1,154) (1,321)
Net cash used in investing activities (4,823) (1,627) (2,939)
Cash flows from financing activities      
Payment of contingent royalty obligation to Evolus Founders (7,441) (5,537) (4,185)
Proceeds from issuance of long-term debt, net of discounts 0 50,000 0
Payments for debt issuance costs 0 (46) (500)
Proceeds from follow-on offering, net of underwriting fees 51,211 0 0
Payments for offering costs (248) 0 0
Cash proceeds from exercise of stock options 4,882 231 539
Tax withholding paid on behalf of employees for net share settlement (990) (7) 0
Net cash provided by (used in) financing activities 47,414 44,641 (4,146)
Effect of exchange rates on cash and cash equivalents (478) (90) (337)
Change in cash and cash equivalents 24,114 8,916 (92,334)
Cash and cash equivalents, beginning of period 62,838 53,922 146,256
Cash and cash equivalents, end of period 86,952 62,838 53,922
Supplemental disclosure of cash flow information      
Cash paid for interest 17,545 12,708 7,999
Cash paid for income taxes 235 117 76
Non-cash investing and financing information      
Operating lease right-of-use assets obtained in exchange for operating lease liabilities 3,002 4,550 0
Issuance of common stock in connection with Symatese Europe Agreement $ 0 $ 1,476 $ 0